Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca emphasizing transparency

Executive Summary

In efforts to increase transparency, AstraZeneca plans to make medical education grants, third party contributions and post-marketing study commitments public this fall, and political contribution postings are expected in the second quarter. "We understand that to make a difference to patient health it's important for us to be open," AstraZeneca told "The Pink Sheet." The information will be available through a link on the company site, and some that is already public, such as clinical trial data and compliance program information, will be made more visible

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel